<?xml version="1.0" encoding="UTF-8"?>
<abstract id="pbi13194-abs-0001">
 <title>Summary</title>
 <p>Chikungunya virus (
  <styled-content style="fixed-case" toggle="no">CHIKV</styled-content>) is a mosquito‐transmitted alphavirus, and its infection can cause long‐term debilitating arthritis in humans. Currently, there are no licensed vaccines or therapeutics for human use to combat 
  <styled-content style="fixed-case" toggle="no">CHIKV</styled-content> infections. In this study, we explored the feasibility of using an anti‐
  <styled-content style="fixed-case" toggle="no">CHIKV</styled-content> monoclonal antibody (
  <styled-content style="fixed-case" toggle="no">mA</styled-content>b) produced in wild‐type (
  <styled-content style="fixed-case" toggle="no">WT</styled-content>) and glycoengineered (∆
  <styled-content style="fixed-case" toggle="no">XFT</styled-content>) 
  <italic>Nicotiana benthamiana</italic> plants in treating 
  <styled-content style="fixed-case" toggle="no">CHIKV</styled-content> infection in a mouse model. 
  <styled-content style="fixed-case" toggle="no">CHIKV mA</styled-content>b was efficiently expressed and assembled in plant leaves and enriched to homogeneity by a simple purification scheme. While 
  <styled-content style="fixed-case" toggle="no">mA</styled-content>b produced in ∆
  <styled-content style="fixed-case" toggle="no">XFT</styled-content> carried a single N‐glycan species at the Fc domain, namely GnGn structures, 
  <styled-content style="fixed-case" toggle="no">WT</styled-content> produced 
  <styled-content style="fixed-case" toggle="no">mA</styled-content>b exhibited a mixture of N‐glycans including the typical plant GnGn
  <styled-content style="fixed-case" toggle="no">XF</styled-content>
  <sub>3</sub> glycans, accompanied by incompletely processed and oligomannosidic structures. Both 
  <styled-content style="fixed-case" toggle="no">WT</styled-content> and ∆
  <styled-content style="fixed-case" toggle="no">XFT</styled-content> plant‐produced 
  <styled-content style="fixed-case" toggle="no">mA</styled-content>bs demonstrated potent 
  <italic>in vitro</italic> neutralization activity against 
  <styled-content style="fixed-case" toggle="no">CHIKV</styled-content>. Notably, both 
  <styled-content style="fixed-case" toggle="no">mA</styled-content>b glycoforms showed 
  <italic>in vivo</italic> efficacy in a mouse model, with a slight increased efficacy by the ∆
  <styled-content style="fixed-case" toggle="no">XFT</styled-content>‐produced 
  <styled-content style="fixed-case" toggle="no">mA</styled-content>bs. This is the first report of the efficacy of plant‐produced 
  <styled-content style="fixed-case" toggle="no">mA</styled-content>bs against 
  <styled-content style="fixed-case" toggle="no">CHIKV</styled-content>, which demonstrates the ability of using plants as an effective platform for production of functionally active 
  <styled-content style="fixed-case" toggle="no">CHIKV mA</styled-content>bs and implies optimization of 
  <italic>in vivo</italic> activity by controlling Fc glycosylation.
 </p>
</abstract>
